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Abstract 
Objective: To compare maternal hemodynamics and perinatal outcomes in women 
identified at 11-13 weeks’ gestation as being screen positive (N=170) or negative 
(N=926) for preterm preeclampsia (PE) by a combination of maternal factors, mean 
arterial pressure, uterine artery pulsatility index and serum placental growth factor 
and pregnancy associated plasma protein-A.  
Methods: This was a prospective, longitudinal cohort study of maternal 
cardiovascular function, assessed by a bioreactance method, in women undergoing 
first trimester screening for PE. We investigated screen positive and screen negative 
women that did not have medical co-morbidities, did not develop PE or pregnancy 
induced hypertension (PIH) and delivered livebirths at term with birthweight between 
the 5th to 95th percentiles. A multilevel linear mixed-effects model was performed to 
compare the repeated measures of the cardiac variables controlling for maternal 
characteristics.  
Results: The screen negative group had normal cardiac function changes across 
gestation, whereas, the screen positive group demonstrated static or reducing 
cardiac output and stroke volume and higher mean arterial pressure and peripheral 
vascular resistance with advancing gestation. In the screen-positive, compared to 
screen-negative women, the birth-weight z-score was shifted to the left with about 
70% higher prevalence of babies below the 35th, 30th or 25th percentile, and the 
rate of operative delivery for fetal distress in labour.  
Conclusions: Patients who screen positive for impaired placentation, even if they do 
not develop PE or deliver SGA neonates, have pathological cardiac adaptation in 
pregnancy and increased risk of adverse perinatal outcome.  
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Introduction 
In normal pregnancy, cardiac output (CO) increases with gestational age and by 24 
weeks the increase is up to 45% compared to non-pregnant levels.1, 2 Conversely, 
peripheral vascular resistance (PVR) decreases by about 35% from pre-pregnancy 
levels, reaches a nadir during the middle of the second trimester and subsequently 
increases for the remainder of the pregnancy.3, 4 These changes are the required 
mechanisms for the body to meet the increased metabolic demands of the mother 
and fetus and to ensure adequate uteroplacental circulation and fetal growth.5, 6  
Maladaptation of the maternal cardiovascular system, from as early as the first 
trimester of pregnancy, plays a pivotal role in the pathophysiology of hypertensive 
disorders of pregnancy (HDP) and delivery of small for gestational age (SGA) 
neonates.7 Birth of SGA neonates is associated with a lack of maternal intravascular 
volume expansion, low CO and increased PVR.8-10 This distinct hemodynamic 
phenotype in SGA is not only observed in pregnancies with HDP11 but also in 
normotensive pregnancies.12, 13 
Early-onset PE and SGA are associated with impaired placentation, but it is 
uncertain whether the hemodynamic pattern observed in pregnancies complicated 
by PE and SGA are also present in pregnancies identified by first-trimester screening 
as having evidence of impaired placentation but do not subsequently develop PE or 
deliver SGA neonates. This study attempts to address this question by examining 
the hemodynamic profile and perinatal outcome in pregnancies identified by first-
trimester screening as being at increased risk of impaired placentation but did not 
develop PE or pregnancy induced hypertension (PIH) and delivered livebirths at term 
with birthweight between the 5th to 95th percentiles. The hemodynamic profile and 
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perinatal outcome of these pregnancies were compared to those who were identified 
by first-trimester screening as being at low-risk of impaired placentation.  
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Methods 
Study population 
This prospective, longitudinal study of singleton pregnancies is a sub study of the 
ASPRE trial (Combined multi-marker screening and randomised patient treatment 
with aspirin for evidence-based preeclampsia prevention), involving women with 
singleton pregnancies attending routine pregnancy care at 11+0 to 13+6 week’s 
gestation. The sub-study was conducted from November 2015 to May 2016 in six 
maternity hospitals in the UK. Ethical approval was granted (REC reference: 
13/LO/1479) and R&D approvals were obtained for respective sites.  
During the first visit, PE screening was performed based on a previously reported 
algorithm for first-trimester assessment of risk for preterm-PE by maternal factors, 
mean arterial pressure (MAP), uterine artery mean pulsatility index (UtA-PI), 
pregnancy-associated plasma protein A (PAPP-A) and placental growth factor 
(PlGF).14 Women screen-positive for preterm-PE were offered participation in a 
double blind, randomized trial of Aspirin vs. Placebo in the prevention of PE. They 
were also offered to participate in this sub-study involving hemodynamics monitoring. 
The two study groups of the hemodynamics study comprised of 1) women who 
screened positive for PE (N=430) (Risk of preterm PE >1 in 100) and 2) gestation 
age matched screen-negative controls (N=1148) (Risk of preterm PE <1 in 100). 
Maternal factors, biomarkers, hemodynamics and fetal wellbeing scans were 
assessed upon recruitment (at 11-14 weeks) and repeated at 19-24, 30-34 and 35-
37 weeks. For the ASPRE trial exclusion criteria were maternal age <18 years, 
women already on Aspirin, pre-existing maternal cardiac conditions, fetal 
abnormalities, incomplete follow-up and termination of pregnancy or miscarriage. 
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As both the screen-positive and screen-negative groups were heterogeneous, we 
excluded from this study women with multiple comorbidities (chronic hypertension, 
pre-existing or gestational diabetes mellitus, systemic lupus erythematous or anti-
phospholipid syndrome, asthma, other autoimmune diseases, HIV, hepatitis B or C), 
those using any medication, those that developed PE or GH and those delivering 
preterm or babies with birthweight <5th or >95th percentiles,   because these factors 
would have a significant impact on maternal hemodynamic parameters.  
Maternal factors  
Maternal factors recorded included maternal age, height, weight at each visit, racial 
origin (White, Black, South Asian, East Asian and mixed), method of conception 
(spontaneous or assisted by in-vitro fertilization or use of ovulation drugs), cigarette 
smoking during pregnancy (yes or no), medical history, medications and obstetric 
history (parous or nulliparous if no previous pregnancies at >24 weeks’ gestation), 
and previous PE or FGR (yes or no).  
Maternal cardiovascular function 
Cardiovascular function was assessed using a non-invasive, bioreactance method 
(NICOM, Cheetah Medical Ltd, Maidenhead, Berkshire, UK) validated both in 
pregnant and non-pregnant populations.10, 15, 16 Bioreactance calculates the stroke 
volume via the relative phase shifts occurring when an alternating electrical current 
traverse the thoracic cavity. Four dual-surface electrodes were applied across the 
maternal back and after 15 minutes of rest, cardiovascular variables [CO, stroke 
volume (SV), heart rate (HR), PVR and MAP] were recorded in a sitting position for 
10 minutes at 30-second intervals (20 cycles). The averages of the final 10 cycles of 
hemodynamic recordings were used as the variables included in the analysis.  
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Definitions 
The definitions of non-proteinuric gestational hypertension (GH) and PE were those 
of the International Society for the Study of Hypertension in Pregnancy.17 SGA and 
LGA were defined as birthweight for gestational age <5th percentile and >95th 
percentile, respectively.18  
Statistical analysis 
Maternal demographic and pregnancy outcome characteristics between the two 
groups were compared using the chi-square test or Fisher’s exact test for categorical 
variables. For the comparison of the maternal race and method of conception, we 
present only the overall chi-square test statistic. The Kolmogorov – Smirnov test was 
used to assess the normality of the distribution of the data. As the data were not 
normally distributed, the Mann – Whitney U-test was used to compare continuous 
data. Data are presented as median (interquartile range) for continuous variables 
and as n (%) for categorical variables. 
Comparison of repeat measures of maternal weight, body surface area, CO, SV, HR, 
MAP and PVR between the four visits was performed using Friedman’s test with the 
Dunn-Bonferroni correction for the post-hoc analysis. 
For the repeated measures analysis of the maternal hemodynamic variables, 
controlling for demographic characteristics and time (the four visits), a multilevel 
linear mixed-effects model was performed. Linear mixed effects are statistical 
models for repeated data analysis. They incorporate both fixed and random effects 
and provide information for both the within and between subject variability. Fixed 
effects are considered those variables that all possible values in which a researcher 
is interested are present in the study, whilst random effects are those that the study 
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contains only a random sample of possible variable values.19  They are more robust 
when dealing with missing values in longitudinal studies, compared to the traditional 
repeat measures ANOVA, and hence it is gradually becoming the preferred method 
for repeat measures analysis.   
The distribution of maternal weight, CO, SV, MAP and PVR were made Gaussian 
after log10 transformation. The fixed-effect component included time (the four visits), 
group (screen-negative versus screen-positive), maternal age, weight, height, race, 
conception, smoking, family history of a hypertensive disorder of pregnancy, 
nulliparity and first-order interaction between time and group. The likelihood radio 
(LR) test was used to define the best multilevel model (including only the random 
slope for time or random intercept versus including both the random intercept and 
slope) and to compare it with the base-model (with no random effects). The fixed and 
random effects of the multilevel models and the estimated marginal means at the 
four visits are presented.  
The software program IBM SPSS Statistics 23 (SPSS Inc., Chicago, IL, USA) were 
used for the statistical analysis (IBM Corp, Released 2015, IBM SPSS Statistics for 
Windows, Version 23.0. Armonk, NY: IBM Corp). 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Results 
For the maternal hemodynamic studies, 1520 and 505 women with singleton 
pregnancies who were screen-negative and positive for preterm-PE, respectively, 
were recruited at the initial visit of the ASPRE trial. We excluded from the study 373 
patients of the screen-negative and 78 from the screen-positive cohort due to 
miscarriage, preterm delivery, fetal anomalies, poor signal from the bioreactance 
monitor and incomplete follow-up (Figure 1). The remaining study population of 1146 
from the screen-negative group and 427 from the screen-positive group were 
included for the hemodynamic studies. For the current study, we included 926 from 
the screen-negative group and 170 women from the screen-positive group. 
respectively, who fulfilled the entry criteria. In the screen positive group, 88 patients 
were randomised to aspirin and 82 to placebo. 
Maternal demographics and pregnancy outcomes 
The maternal characteristics for the two groups of women at the screening visit are 
presented in Table 1. The screen-positive women were heavier and taller, were more 
likely to be primiparous and of Black race and were more likely to have a family 
history of PE and to have conceived by in-vitro fertilization. Conversely, in the 
screen-negative group, multiparous women with no previous history of PE/FGR, 
White race and spontaneous conception were significantly more prevalent when 
compared to the screen-positive cohort. Despite being normotensive, the systolic, 
diastolic and MAP during the screening visit was significantly higher in the screen-
positive compared to the screen negative group. 
Both cohorts delivered babies between the 5th and 95th centiles and at similar 
gestational ages at term, they had the same rate and reasons for induction of labour 
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and rates and days of admission to the neonatal unit (NNU) (Table 1 and 
Supplementary table 1). Only seven patients in the screen-negative and two in the 
screen-positive group were induced for estimated weight between the 5th and 10th 
percentile with normal fetal Dopplers, a non-statistically significant difference 
(Supplementary table 1). All of them delivered babies with birthweight above the 5th 
percentile. However, the distribution of birth-weight z-score was shifted to the left 
with about 70% higher prevalence of babies below the 35th, 30th or 25th percentile in 
the screen-positive compared to screen-negative women (Table 1, Figure 2). 
Furthermore, the rate of emergency caesarean section and operative delivery for 
fetal distress in labour was higher in the screen positive compared to the screen 
negative group (Table 1). There were no differences between the two groups in 
terms of NNU admission, ventilation, respiratory distress syndrome, sepsis or 
neonatal hypoglycemia (Table 1). 
Multilevel linear mixed-effects models (see supplementary results) 
The fixed and random effects of the best multilevel models are shown in 
Supplementary Table 2 and the estimated marginal means are shown in 
Supplementary Table 3 and Figures 3 and 4. 
Log10CO in the screen-negative group, demonstrated an increase during the first 
three visits and a decline thereafter. On the contrary in the screen-positive group, 
Log10CO demonstrated a linear decline with gestation. The two groups demonstrated 
opposing changes with gestation in Log10SV. The screen-negative group 
demonstrated an increase in SV in the first three visits with a decline after that, whilst 
the screen-positive group showed a progressive decline with gestation. HR in both 
groups, demonstrated an increase with gestation during the first three visits. In the 
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fourth visit, the HR reached a plateau in the screen-negative group whilst the screen-
positive group showed a decline. Log10MAP in both groups, demonstrated a similar 
change with gestation with a decline in the first three visits followed by an increase in 
the fourth visit. Log10MAP levels were higher throughout gestation in the screen-
positive group. Log10PVR in the screen-negative group, demonstrated a decline 
during the first three visits and a slight increase after that. On the contrary, in the 
screen-positive group, Log10PVR demonstrated an increase with gestation. 
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Discussion 
The results of this study demonstrate that healthy women, who screen-positive for 
preterm-PE,20 even if normotensive and delivered at term, exhibit a pathological 
cardiovascular adaptation in pregnancy. They have a static hemodynamic profile 
with a decline in CO and SV and higher MAP and PVR compared to healthy women 
who screen-negative. The birthweight distribution of this group was skewed to the 
left with about 70% higher prevalence of babies below the 35th, 30th or 25th percentile 
compared to screen-negative women, indicating a higher prevalence of placental 
insufficiency. As a surrogate marker for placental disease, they had about 50% more 
operative deliveries due to fetal distress in labour.  
Our results in the screen-negative group, agree with the known changes of maternal 
cardiac function in normal pregnancy with a decline in PVR and MAP from the first 
trimester and a concomitant increase in maternal CO and SV until early in the third 
trimester.21-24 Thereafter, an increase in MAP and PVR and a decline in CO and SV 
until term denote an increase in afterload and a decline in left ventricular systolic 
function.21, 23, 24 Furthermore, the magnitude of change from the screening visit at 11-
14 weeks to the second visit at 19-24 weeks is comparable to that described in a 
recent meta-analysis that showed about 10% and 5% increase in CO and SV, 
respectively, and a 20% decline in PVR between the first and second trimester.23 
Like other studies in normal pregnancy, we also identified a peak CO early in the 
third trimester, followed by a decline towards term.21, 24-26 The majority of the 
increase in CO in the second visit appears to be mainly due to the persistent rise in 
HR, rather than the modest 5% increase in SV. Thereafter, the maternal CO appears 
to be driven by the rise in HR, as SV declines towards term, possibly as a result of 
the increase in afterload.26  
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On the contrary, CO and PVR in the screen-positive women demonstrated an 
opposite pattern. The decline in SV throughout gestation could not be compensated 
by the rise in HR, resulting in mild drop of CO. PVR remained static across gestation, 
a failure of the cornerstone of hemodynamic maternal adaptation in early pregnancy. 
Previous studies on maternal hemodynamics performed either in hypertensive 
populations27-29 or on normotensive cohorts10-12, 30-36 had similar findings of a low CO 
and raised PVR in pregnancies with FGR.   
The fact that this hemodynamic pattern was associated with a shift to the left in the 
distribution of birthweight and with a higher prevalence of operative deliveries for 
fetal distress is suggestive of a degree of placental insufficiency. This was either mild 
enough not to be manifested clinically during pregnancy, or it was a false negative of 
the serial growth scans in the background of maternal normal blood pressure, or it 
evolved during the last five weeks of gestation, after the last visit at 36 weeks. In any 
case, the maternal hemodynamic profile demonstrates that the FMF algorithm 
screens positive a group of women at high risk for placental insufficiency who 
warrant close surveillance at term.  
We have excluded from our study babies with birthweight below the 5th and above 
the 95th percentiles to avoid reporting on adverse outcomes secondary to severe 
growth restriction or macrosomia. Despite the population selection, the screen-
positive group contained a high proportion of mothers with impaired cardiovascular 
adaptation and hence it is not surprising that their babies had undiagnosed placental 
insufficiency with higher rates of operative birth due to fetal distress. The inability of 
an undiagnosed growth restricted fetus to cope with the stress of labour may be 
linked to the impaired expansion of maternal CO. The screen-positive women would 
struggle to accommodate the 12% and 34% increase in CO associated with the first 
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and second stage labor, respectively,2, 37 or the hypovolemic stress after epidural 
anesthesia.38, 39 It is thus unsurprising that women with low CO and high PVR had 
more intrapartum feto-maternal complications,40 as also demonstrated in this study.  
This is the first study that utilises a validated combined multi-marker screening 
method to select a ‘high and low risk for PE’ cohort for comparison of maternal 
hemodynamics. The longitudinal nature of the study and the large sample size are its 
main strengths. Furthermore, the selection of an operator independent,16, 41 non-
invasive cardiac monitor maximised patient participation and reduced bias across the 
multiple sites of the study. The stringent methodology in patient selection meant that 
we could reliably examine the serial changes in pregnancy of the maternal 
hemodynamics without the confounding effect of medical co-morbidities, medications 
or potentially compromised cardiovascular systems in women with previous HDP 
and FGR.  
A limitation of this study is that we do not have postnatal follow-up and were unable 
to ascertain whether these hemodynamic patterns are evident only during a period of 
cardiovascular strain, such as pregnancy, or whether they persist in the non-
pregnant state. Furthermore, the design of the ASPRE trial included assessments up 
until 37 weeks’ gestation. It is possible that had more visits been performed until 
delivery, a higher proportion of babies with suspected growth restriction would have 
been detected and hence their pregnancy management modified. However, with the 
constraints of routine clinical care, this may not be possible to achieve and therefore, 
the maternal hemodynamic profiles may play a significant role in highlighting 
pregnancies that need closer surveillance at term. Another limitation of the study is 
the high proportion of women in the screen negative group that withdrew consent 
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from the study or did not attend for all four visits (194/1519); consequently, there is a 
risk of a certain degree of selection bias.  
In conclusion, patients who screen-positive for preterm-PE have impaired cardiac 
adaptation in pregnancy and smaller birthweights. Therefore, they should have 
increased surveillance late in the third trimester and should not be regarded as 
‘normal’ despite remaining normotensive at term as they are at greater risk of occult 
placental insufficiency. Current efforts in creating a prediction model to identify 
FGR10 and those at risk of operative delivery for fetal compromise in SGA fetuses at 
term42 could be improved by incorporating maternal PE screening status and 
hemodynamic studies. Given the inherent error of third trimester fetal biometry 
measurements,43 repeated maternal hemodynamics using a non-operator dependant 
technique in the third trimester could potentially risk-stratify screen-positive 
pregnancies to guide timing of induction of labor if SGA was suspected.  
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Figure legends: 
Figure 1. Flow diagram of recruitment for the maternal hemodynamics studies after 
screening for the ASPRE trial 
 
Figure 2. Birth-weight Z-score distributions for screen-negative (white bars) and 
screen-positive (black bars) women 
 
Figure 3. Linear mixed-effects model: Estimated marginal means of Log10Cardiac 
output (A), Log10Stroke volume (B) and Heart rate (C) in the four visits after 
controlling for demographic characteristics in the screen-negative (dotted line, white 
circles) and screen-positive (solid line-black circles) groups.  
 
Figure 4. Linear mixed-effects model: Estimated marginal means of Log10Mean 
arterial pressure (A and Log10Peripheral vascular resistance (B) in the four visits 
after controlling for demographic characteristics in the screen-negative (dotted line, 
white circles) and screen-positive (solid line-black circles) groups.  
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Table 1. Demographics and pregnancy outcomes in screen-negative and positive 
women.  
 
 Screen negative 
 (n=926) 
Screen positive 
 (n=170) 
p-value 
Age (years) 31.4 (27.28 – 
34.93) 
31.3 (27.8 – 
34.5) 
0.874 
Weight at booking (kg) 66.8 (60.0 – 77.0) 70.7 (61.5 - 84.9) 0.002 
Height (cm) 165.4 (6.4) 163.7 (7.0) 0.001 
Smoking, n (%) 54 (5.8) 6 (3.5) 0.220 
Primiparous, n (%) 448 (48.4) 140 (81.9) <0.0001 
Multiparous, no previous PE/FGR, 
n (%) 
478 (51.6) 30 (18.1) <0.0001 
Family history of PE (%) 39 (4.2) 18 (10.5) 0.001 
Conception, n (%)   <0.0001 
Spontaneous, n (%) 905 (97.7) 159 (93.5)  
Ovulation drug, n (%) 7 (0.8) 0 (0.0)  
In vitro fertilization, n (%) 14 (1.5) 11 (6.4)  
Ethnicity   <0.0001 
White, n (%) 745 (80.5) 102 (59.6)  
Black, n (%) 97 (10.5) 49 (28.7)  
South Asian, n (%) 36 (3.9) 10 (5.9)   
East Asian, n (%) 21 (2.3) 6 (3.5)  
Mixed, n (%) 27 (2.9) 3 (1.8)  
Systolic blood pressure (mmHg) 113.3 (106.7 – 
120.5) 
118.5 (111.2 –
126.0) 
<0.0001 
Diastolic blood pressure (mmHg) 73.6 (68.7 – 78.5)  77.5 (72.3 – 
82.5)  
<0.0001 
Mean arterial pressure (mmHg) 86.7 (81.7 – 92.3) 90.3 (85.2 – 
96.5) 
<0.0001 
Gestational age at delivery (wks) 40.1 (39.3 – 41.0) 39.7 (39.0 – 
40.7) 
0.004 
Birth-weight (g) 3500 (3229 – 3800) 3280 (3060 – 
3600) 
<0.0001 
Birth weight z-score -0.19 (-0.77 - -0.39) -0.66 (-1.1 – 
0.35) 
<0.0001 
Birth weight percentile 42.5 (22.2 – 65.0) 25.2 (13.6 – 
51.3) 
<0.0001 
5th -10th percentile, n (%) 69 (7.4) 24 (14.1) 0.002 
<25th percentile, n (%) 266 (28.7) 84 (49.0) <0.0001 
<30th percentile, n (%) 319 (34.4) 97 (57.1) <0.0001 
<35th percentile, n (%) 371 (40.0) 111 (65.3) <0.0001 
Induction of labor, n (%) 228 (24.6) 45 (26.5) 0.630 
Emergency LSCS, n (%) 119 (12.9) 32 (18.7) 0.041 
Operative birth for fetal distress, n 
(%) 
96 (10.4) 28 (16.4) 0.023 
NNU admission, n (%) 44 (4.8) 3 (1.8) 0.077 
NNU number of days 3.0 (3.0 – 5.0) 5.0 (1.0 – 5.0) 0.548 
Ventilation, n (%) 10 (1.1) 3 (1.8) 0.454 
Respiratory distress syndrome, n 
(%) 
19 (2.0) 0 (0.0) 0.058 
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Sepsis, n (%) 20 (2.2) 2 (1.2) 0.396 
Neonatal hypoglycemia, n (%) 6 (0.6) 1 (0.6) 0.928 
PE: pre-eclampsia, FGR: fetal growth restriction, NNU: neonatal unit 
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